PROTECT-TIMI 30 Trial

A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents

The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other cardiovascular complications who will undergo surgery to open up blocked arteries in the heart.

Platelet inhibitor drugs

Inclusion Criteria:

• Chest paing/discomfort that occurs at rest and lasts at least 10 minutes and have at least one of the following high-risk features:

  • diabetes
  • elevated cardiac proteins in the blood (indicating acute coronary syndrome)

• Be willing and able to give informed consent

Exclusion Criteria:

• uncontrolled hypertension
• cardiac episode (heart attack) within the previous 24 hours before randomization into the trial
• prior heart surgery (PCI) within the previous 2 weeks before randomizing in the trial
• any electorcardogram (ECG) finding that make the Holter monitor for ischemia unable to read